Analysts Expect Neuronetics Inc (STIM) to Announce -$0.37 Earnings Per Share

Equities analysts expect Neuronetics Inc (NASDAQ:STIM) to report ($0.37) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Neuronetics’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.35). The business is expected to issue its next earnings report on Tuesday, June 4th.

On average, analysts expect that Neuronetics will report full year earnings of ($1.64) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($1.56). For the next year, analysts expect that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.41) to ($1.39). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Neuronetics.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. The company had revenue of $15.64 million for the quarter, compared to the consensus estimate of $14.71 million.

A number of research firms have issued reports on STIM. Piper Jaffray Companies reduced their target price on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research note on Tuesday, March 5th. BTIG Research restated a “buy” rating and issued a $25.00 price objective on shares of Neuronetics in a research note on Wednesday, March 6th. Six investment analysts have rated the stock with a buy rating, Neuronetics has an average rating of “Buy” and an average price target of $31.60.

In other Neuronetics news, VP Peter Donato sold 26,238 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $16.15, for a total value of $423,743.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Neuronetics by 21.5% in the 4th quarter. Geode Capital Management LLC now owns 73,570 shares of the company’s stock worth $1,423,000 after purchasing an additional 13,033 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Neuronetics in the 4th quarter worth about $303,000. RTW Investments LP grew its holdings in shares of Neuronetics by 6.5% in the 4th quarter. RTW Investments LP now owns 167,728 shares of the company’s stock worth $3,246,000 after purchasing an additional 10,241 shares during the last quarter. Partner Fund Management L.P. bought a new stake in shares of Neuronetics in the 4th quarter worth about $444,000. Finally, Bank of America Corp DE grew its holdings in shares of Neuronetics by 967.7% in the 4th quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock worth $111,000 after purchasing an additional 5,245 shares during the last quarter. 69.36% of the stock is currently owned by institutional investors and hedge funds.

STIM traded up $0.32 on Thursday, reaching $15.07. 635 shares of the company traded hands, compared to its average volume of 153,065. Neuronetics has a 52-week low of $13.26 and a 52-week high of $39.39. The company has a market capitalization of $275.33 million and a PE ratio of -5.72. The company has a debt-to-equity ratio of 0.43, a quick ratio of 8.26 and a current ratio of 8.44.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.